Skip to content

BCBS Minnesota

Does BCBS Minnesota cover Ozempic?

Yes. BCBS Minnesota covers Ozempic for type 2 diabetes with prior authorization. Other policy requirements and your plan's benefits also apply.

Policy documents

  • BCBS Minnesota ACA Marketplace prior authorization policy

    BCBS Minnesota · PA policy · Employer and ACA Marketplace

    Effective April 1, 2026. Verified June 5, 2026.

    View PDF Download Original insurer source

  • BCBS Minnesota Employer / Commercial Insurance prior authorization policy

    BCBS Minnesota · PA policy · Employer

    View PDF Download
  • Employer and ACA Marketplace: Covered (preferred drug). See the qualification pathways below.

Earliest policy review April 1, 2026. How we verify · Check your exact plan

Full requirements: Ozempic for Type 2 Diabetes (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered (preferred drug)

Qualification pathways

You can qualify through any one of these.

New Start — Preferred Agent

All of:

  • Diagnosis of type 2 diabetes mellitus
  • A1C ≥ 6.5% confirmed by lab test (lab results or medical records required)
  • Ozempic (semaglutide) is a preferred agent — no step therapy required
  • Age within FDA labeling for the requested indication OR support for use at patient's age
  • Patient will NOT use requested agent in combination with a DPP-4 inhibitor
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to Ozempic

Continuation of Therapy

All of:

  • Diagnosis of type 2 diabetes mellitus
  • A1C ≥ 6.5% confirmed by lab test
  • Ozempic is listed as eligible for continuation of therapy
  • Age within FDA labeling for the requested indication OR support for use at patient's age
  • Patient will NOT use requested agent in combination with a DPP-4 inhibitor
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to Ozempic

Plus any one of:

  • Patient has been treated with a preferred agent (not samples) within the past 90 days
  • Prescriber states patient has been treated with a preferred agent within the past 90 days (not samples) and is at risk if therapy is discontinued

Documentation to bring

  • Documentation of type 2 diabetes mellitus diagnosis
  • Lab result confirming A1C ≥ 6.5% (or medical records)
  • Attestation that patient will not use Ozempic in combination with a DPP-4 inhibitor
  • Attestation that patient will not use Ozempic in combination with another GLP-1 receptor agonist
  • Confirmation that patient has no FDA labeled contraindications to Ozempic
  • For continuation: documentation or prescriber statement of prior preferred agent use within past 90 days (samples not approvable)

Quantity limits

  • 2 MG/3ML, 4 MG/3ML, 8 MG/3ML — 1 pen

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months

Not covered when

  • Combination use with DPP-4 inhibitor agents
  • Combination use with another GLP-1 receptor agonist
  • FDA labeled contraindications to Ozempic (personal or family history of MTC or MEN2; prior serious hypersensitivity)

Policy note: Ozempic (semaglutide) is listed as a preferred agent. The FDA label also includes indications for CV risk reduction and CKD in T2DM patients, but this PA policy document only establishes criteria under a diabetes (glycemic control) module — no separate CV risk reduction or CKD criteria are established in this document. The BCBS MN Step Therapy Supplement also applies. Quantity limit: 1 pen per 28 days across all strengths.

Policy effective April 1, 2026 · verified June 5, 2026 · source: BCBS Minnesota ACA Marketplace prior authorization policy · View policy document (PDF)

Open on its own page →

Full requirements: Ozempic for Heart Disease Risk Reduction (1 plan type)

Applies to Employer plans.

Covered (preferred drug)

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction - Ozempic in T2DM with Established CVD or Multiple CV Risk Factors

All of:

  • Diagnosis of type 2 diabetes
  • A1C ≥ 6.5% confirmed by lab test
  • Requested agent will be used to reduce risk of major adverse cardiovascular events (cardiovascular death, non-fatal MI, or non-fatal stroke)
  • Patient will NOT use requested agent in combination with a DPP-4 containing agent
  • Patient will NOT use requested agent in combination with another GLP-1 or GLP-1/GIP receptor agonist
  • No FDA labeled contraindications to the requested agent

Plus any one of:

  • Patient has established cardiovascular disease (e.g., MI, stroke, any revascularization procedure, TIA, unstable angina, amputation, symptomatic or asymptomatic coronary artery disease)
  • Patient has multiple cardiovascular risk factors (e.g., hypertension, dyslipidemia, family history of cardiovascular disease, smoking)

Documentation to bring

  • Documentation of type 2 diabetes diagnosis
  • Lab test results showing A1C ≥ 6.5%
  • Documentation of established cardiovascular disease (e.g., MI, stroke, revascularization, TIA, unstable angina, amputation, CAD) or documentation of multiple cardiovascular risk factors (HTN, dyslipidemia, family history of CVD, smoking)
  • Prescriber statement that the requested agent will be used to reduce risk of major adverse cardiovascular events
  • Confirmation that patient is not using a DPP-4 inhibitor concurrently
  • Confirmation that patient is not using another GLP-1 or GLP-1/GIP receptor agonist concurrently

Quantity limits

  • 2 MG/3ML — 1 pen per 28 days
  • 4 MG/3ML — 1 pen per 28 days
  • 8 MG/3ML — 1 pen per 28 days

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: Continuation approved via same criteria as initial approval. Patient must still have T2DM diagnosis and A1C ≥ 6.5%. Continuation pathway also available if patient has been on a preferred agent within past 90 days.

Not covered when

  • Concurrent use with DPP-4 inhibitors
  • Concurrent use with another GLP-1 or GLP-1/GIP receptor agonist
  • Personal or family history of MTC or MEN 2
  • Type 1 diabetes

Policy note: CV risk reduction indication for Ozempic applies in patients with T2DM and established CVD or multiple CV risk factors. The policy does not exclude patients who have NOT failed metformin/insulin if the CV risk pathway is used — metformin/insulin trial is NOT required for this pathway. T2DM diagnosis and A1C ≥ 6.5% are still required. This is a bundled policy covering all GLP-1 indications under a single PA framework; the CV risk pathway is a qualifying exception to the metformin/insulin step therapy requirement.

source: BCBS Minnesota Employer / Commercial Insurance prior authorization policy · View policy document (PDF)

Open on its own page →

Full requirements: Ozempic for Kidney Disease (CKD) (1 plan type)

Applies to Employer plans.

Covered (preferred drug)

Qualification pathways

You can qualify through any one of these.

CKD Indication - Ozempic in T2DM with CKD

All of:

  • Diagnosis of type 2 diabetes
  • A1C ≥ 6.5% confirmed by lab test
  • Patient has chronic kidney disease (CKD)
  • Requested agent will be used to reduce risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death
  • Patient will NOT use requested agent in combination with a DPP-4 containing agent
  • Patient will NOT use requested agent in combination with another GLP-1 or GLP-1/GIP receptor agonist
  • No FDA labeled contraindications to the requested agent

Documentation to bring

  • Documentation of type 2 diabetes diagnosis
  • Lab test results showing A1C ≥ 6.5%
  • Documentation of chronic kidney disease (CKD) diagnosis
  • Prescriber statement that the requested agent will be used to reduce risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death
  • Confirmation that patient is not using a DPP-4 inhibitor concurrently
  • Confirmation that patient is not using another GLP-1 or GLP-1/GIP receptor agonist concurrently

Quantity limits

  • 2 MG/3ML — 1 pen per 28 days
  • 4 MG/3ML — 1 pen per 28 days
  • 8 MG/3ML — 1 pen per 28 days

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: Continuation approved via same criteria as initial approval, or via the continuation of therapy pathway if patient has been on a preferred agent within past 90 days.

Not covered when

  • Concurrent use with DPP-4 inhibitors
  • Concurrent use with another GLP-1 or GLP-1/GIP receptor agonist
  • Personal or family history of MTC or MEN 2
  • Type 1 diabetes

Policy note: CKD indication for Ozempic (to reduce risk of sustained eGFR decline, ESKD, and cardiovascular death in T2DM with CKD) is recognized as an exception pathway to the metformin/insulin step therapy requirement. Specific eGFR or UACR thresholds are not defined in this policy document. T2DM diagnosis and A1C ≥ 6.5% are still required per the overall PA framework.

source: BCBS Minnesota Employer / Commercial Insurance prior authorization policy · View policy document (PDF)

Open on its own page →

Questions people ask
Does BCBS Minnesota cover Ozempic?
Yes. BCBS Minnesota covers Ozempic for type 2 diabetes with prior authorization. Other policy requirements and your plan's benefits also apply.
How long does a Ozempic approval last with BCBS Minnesota?
Type 2 Diabetes — Applies to Employer and ACA Marketplace plans. Initial approval: 12 months. Renewal: every 12 months. Heart Disease Risk Reduction — Applies to Employer plans. Initial approval: 12 months. Renewal: every 12 months. Kidney Disease (CKD) — Applies to Employer plans. Initial approval: 12 months. Renewal: every 12 months.
What does BCBS Minnesota require to renew Ozempic?
Heart Disease Risk Reduction — Applies to Employer plans. Continuation approved via same criteria as initial approval. Patient must still have T2DM diagnosis and A1C ≥ 6.5%. Continuation pathway also available if patient has been on a preferred agent within past 90 days. Kidney Disease (CKD) — Applies to Employer plans. Continuation approved via same criteria as initial approval, or via the continuation of therapy pathway if patient has been on a preferred agent within past 90 days.
How current is this information?
The oldest review date among the policies on this page is April 1, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS Minnesota: Mounjaro, Wegovy, Zepbound

Ozempic under other plans: BCBS Alabama, BCBS Arizona, BCBS Arkansas, BCBS Kansas, BCBS Louisiana, BCBS Massachusetts, BCBS Michigan, BCBS Mississippi

All insurance plans · All medications

Summary of BCBS Minnesota's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.